Sanofi received FDA approval for Sarclisa Escena, a subcutaneous treatment for multiple myeloma. This marks the first anticancer therapy approved for administration via a wearable, on-body injector. The device provides a less burdensome alternative to traditional intravenous infusions.
A Phase 3 study demonstrated that the subcutaneous method offers efficacy similar to the intravenous version. The new delivery system significantly reduces treatment times. The injector also results in fewer infusion-related reactions.
This approval strengthens Sanofi’s product pipeline as the company seeks to diversify. The move aims to reduce Sanofi's reliance on its blockbuster drug, Dupixent.